Mucin 5B/MUC5B CRISPR/Cas9 KO Plasmid (h): sc-401077
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Mucin 5B/MUC5B CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Mucin 5B/MUC5B genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Mucin 5B/MUC5B Antibody (5B#19-2E): sc-21768
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mucin 5B/MUC5B CRISPR/Cas9 KO Plasmid (h) | sc-401077 | 20 µg | $397.00 |
Overview
MUC5B encodes mucin 5B, a high–molecular weight, gel-forming secreted mucin that is a major structural component of airway and salivary mucus. Through extensive O-glycosylation and polymerization, MUC5B contributes to mucociliary clearance, pathogen trapping, and epithelial barrier homeostasis, and its expression is regulated by inflammatory and differentiation programs in secretory epithelia. Altered MUC5B abundance or rheological properties are linked to dysregulated mucus transport and chronic airway remodeling, and genetic and expression changes have been associated with lung fibrosis and muco-obstructive lung disease phenotypes. As a readout-rich secreted glycoprotein, MUC5B is widely studied in epithelial differentiation, ER/Golgi secretory processing, and innate defense signaling contexts.
Mucin 5B/MUC5B CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MUC5B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MUC5B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MUC5B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Mucin 5B/MUC5B protein expression.
This CRISPR knockout system enables efficient generation of MUC5B-deficient cell models for investigation of Mucin 5B/MUC5B signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MUC5B exon(s) critical for Mucin 5B/MUC5B function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MUC5B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Mucin 5B/MUC5B CRISPR/Cas9 KO Plasmid (h) and Mucin 5B/MUC5B CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MUC5B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Mucin 5B/MUC5B HDR Plasmid (h) and Mucin 5B/MUC5B HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MUC5B homology arms to support homology-directed repair at defined MUC5B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.